# 1 Performance of RT-PCR on saliva specimens

# 2 compared to nasopharyngeal swabs for the

# **3 detection of SARS-CoV-2 in children: A prospective**

# 4 comparative clinical trial

Yves Fougère <sup>1</sup>, Jean Marc Schwob <sup>2</sup>, Alix Miauton <sup>2</sup>, Francesca Hoegger <sup>3</sup>, Onya Opota <sup>4</sup>, Katia Jaton <sup>4</sup>, Rene Brouillet <sup>4</sup>, Gilbert Greub <sup>4,5</sup>, Blaise Genton <sup>2,5</sup>, Mario Gehri <sup>3</sup>, Ilaria Taddeo <sup>6</sup>, Valérie D'Acremont <sup>2,5</sup>, Sandra A. Asner <sup>1,5,7</sup> 5 6 7 1 Pediatric Infectious Diseases and Vaccinology Unit, Department Women-Mother-8 9 Child, Lausanne University Hospital, Switzerland 10 2. Tropical and Travel Medicine Unit, Center for Primary Care and Public Health 11 (Unisanté), Switzerland 12 3 Service of Pediatrics, Department Women-Mother-Child, Lausanne University 13 Hospital, Switzerland 14 4. Institute of Microbiology, Lausanne University Hospital, Switzerland 15 5. University of Lausanne 16 6 Pediatric Emergency Center, Vidy-Med, Lausanne, Switzerland 17 7. Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, University of Lausanne, Switzerland 18 19 Keywords: SARS-COV-2, saliva, Viral loads, children, sensitivity 20 Running title: Saliva PCR for SARS-CoV-2 detection in children 21 **Corresponding author:** 22 Sandra A Asner, MD, MSc 23 Pediatric Infectious Diseases and Vaccinology Unit 24 Department Mother-Woman-Child; Lausanne University Hospital 25 Rue du Bugnon 46; CH-1011 Lausanne, Switzerland 26 Phone: +41 21 314 10 79, email: Sandra.Asner@chuv.ch

27 ORCID iD: 0000-0001-7911-0752

#### 29 ABSTRACT

- 30 **Background:** Saliva RT-PCR is an attractive alternative for the detection of SARS-
- 31 CoV-2 in adults with much less known in children.
- 32 **Methods:** Children and adolescents with symptoms suggestive of COVID-19 were
- 33 prospectively enrolled in a comparative clinical trial of saliva and nasopharyngeal
- 34 (NP) RT-PCR between November and December 2020. Detection rates and
- 35 sensitivities of saliva and NP RT-PCR were compared. Participants with discordant
- 36 NP and saliva RT-PCR results including viral load (VL) were also analyzed.
- 37 **Result:** Out of 405 patients enrolled, 397 patients had two tests performed. Mean
- 38 age was 12.7 years (range 1.2-17.9). Detection rates were 22.9% (95%Cl 18.8-
- 39 27.1%) by saliva RT-PCR, 25.4% (21.2-29.7%) by NP RT-PCR, and 26.7% (22.4-
- 40 31.1%) by any test. The sensitivity of saliva was 85.2% (78.2-92.1%) when using NP
- 41 as the gold standard; in contrast, when saliva was considered the gold standard, the
- 42 sensitivity of NP was 94.5% (89.8-99.2%). For a NP RT-PCR VL threshold of  $\geq 10^3$
- 43 and  $\geq 10^4$  copies/ml, sensitivity of saliva increases to 88.7% and 95.2% respectively.
- 44 Sensitivity of saliva and NP swabs was respectively 89.5% and 95.3% in patient with
- 45 symptoms less than 4 days (p=0.249) and 70.0% and 95.0% in those with symptoms
- $46 \ge 4$  to 7 days (p=0.096). The 15 patients who had an isolated positive NP RT-PCR
- 47 were significantly younger (p=0.034), had a lower NP VL (median  $5.6 \times 10^3 \text{ vs } 3.9 \times 10^7$ ,
- 48 p<0.001), and were not able to drool saliva at the end of the sampling (p=0.002). VLs
- 49 were significantly lower with saliva PCR than with NP RT-PCR (median 8.7 cp/ml
- 50  $x10^4$ ; IQR 1.2 $x10^4$ -5.2 $x10^5$ ; vs median 4.0 $x10^7$  cp/ml; IQR 8.6 $x10^5$ -1. $x10^8$ ; p<0.001).
- 51

52 Conclusion: Saliva PCR shows diagnostic performances close to NP RT-PCR for

53 SARS-CoV2 detection in most symptomatic outpatient children and adolescents.

#### 54 Introduction

55 Diagnosis for SARS-CoV-2 is pivotal in the management of Coronavirus disease

56 2019 (COVID-19). Accurate and prompt testing of symptomatic children is the

57 foundation for public health decision-making and implementation of appropriate

58 measures including isolation and quarantine  $^{1}$ .

59 The Infectious Diseases Society of America (IDSA) guidelines recommend testing for

60 SARS-CoV-2 by RT-PCR on specimens including NP swabs, mid-turbinate swabs,

nasal swabs or saliva swabs, NP swabs being referenced as the gold standard

62 specimen <sup>2,3</sup>. However, NP swab collection is an unpleasant procedure that can

63 sometimes result in mucous membrane erosions with nasal bleeding, especially in

<sup>64</sup> children <sup>4</sup>. In addition, NP swabs require trained staff for collection and can be

hampered by supply shortages in swabs and transport media. Saliva has already

been reported as an attractive alternative for the detection of SARS-CoV-2 and other

<sup>67</sup> respiratory viruses such as Influenza in adult patients <sup>3,5</sup>. A recent meta-analysis,

reported a sensitivity of 83.2% (95%Cl 74.7-91.4%) and 84.8% (95%Cl 76.8-92.4%)

69 for saliva and NP samples respectively  $^{6}$ .

The use of NP swabs for SARS-CoV-2 detection limits the widespread screening of children <sup>7</sup>. Given the overlap of symptoms caused by SARS-CoV-2 and other respiratory viruses, children qualify for SARS-CoV-2 testing very often. As a result, a simple specimen collection such as saliva that avoids unnecessary discomfort is particularly attractive in children. Saliva collection has also a practical advantage

75	since it can be performed quickly by the patient itself or by the caregiver. Altogether,
76	the use of saliva specimens would speed up the collection process <sup>7</sup> .
77	Pediatric evidence for the use of saliva specimens by RT- PCR for detection of
78	SARS-CoV-2 remains weak with sensitivities varying from 52.9% up to 85.0%
79	reported from small sample sizes when using NP as the gold standard. $^{8,9}$ This
80	ancillary study of the adult RADICO project $^{10}$ aims to prospectively compare the
81	paired saliva and NP samples collected from symptomatic children consulting in
82	outpatient settings for the detection of SARS-CoV-2. The secondary objectives were
83	to compare discordant NP and saliva RT-PCR findings as well as their VL.

84

#### 85 Methods

### 86 Study design, setting and populations

87 This study is an observational prospective multicenter comparative study. Children 88 aged 1 month to 18 years were recruited from two different outpatient clinics in 89 Lausanne (Montétan screening site, Department Mother-Woman-Child; Lausanne 90 University Hospital and Vidy-Med Pediatric Emergency Center) when presenting with 91 symptoms compatible with COVID-19 according to national guidelines(check.bagcoronavirus.ch/screening)<sup>11</sup>. Children aged 12 and over who reported at least one of 92 93 the following symptom including fever, respiratory symptoms such as cough, throat 94 pain, dyspnea or thoracic pain, anosmia, dysgeusia or a least one minor symptom 95 and close contact with a documented COVID-19 case were invited to be tested for SARS-CoV-2 (check.bag-coronavirus.ch/screening). Testing criteria\_were more 96 restrictive for children under 12 years of age<sup>11</sup> (www.coronabambini.ch). For children 97

98	without known contact with a SARS-CoV-2 positive case, testing criteria included a
99	new onset of fever (>38.5 C), a severe cough associated with a bad general
100	condition or the same symptoms persisting over 3 days in those with a good general
101	condition. In addition, children with a good clinical condition presenting with a new
102	onset of fever or a severe cough associated with other COVID-19 compatible
103	symptoms such as gastrointestinal symptoms, myalgia, headaches, or
104	anosmia/ageusia were also tested for SARS-CoV-2. Children with any symptom
105	exposed to a confirmed SARS-CoV-2 positive index case were also tested for SARS-
106	CoV-2.
107	Informed consent from the legal guardians or adolescents ≥14 years were mandatory

- 108 for inclusion. Exclusion criteria included hospitalized children, those requiring
- 109 anticoagulation, and children with a documented past SARS-CoV-2 infection.
- 110 This study was approved by the ethics committee of Canton de Vaud (CER-VD 2020-
- 111 02269) and conducted in accordance with the principles of the Declaration of
- 112 Helsinki, the standards of Good Clinical Practice, and Swiss regulatory requirements.

#### 113 Study procedures

114 Saliva specimens for RT-PCR analyses were collected either by a healthcare

- 115 professional, the patient itself, or its caregiver under supervision, following a
- standard procedure that included swabbing of the oral mucosa and drooling saliva in
- 117 a tube when possible <sup>10,12</sup>. The healthcare professional collected concomitantly one
- 118 NP swab for RT-PCR. Saliva and NP samples collected in viral transport media
- 119 (VTM) were sent the same day or the next morning to the molecular diagnostics
- 120 laboratory for RT-PCR analyses.

121 General information including age, gender, type and duration of symptoms, and

- 122 information on the quality of the saliva sample were collected by the healthcare
- 123 worker on an electronic case report form (REDCap®). The results of both NP swabs
- 124 and saliva samples were next reported in REDCap® by the study investigators.

#### 125 SARS-CoV-2 RT-PCR, cycle thresholds (CT) and viral load (VL) quantification

- 126 SARS-CoV-2 RT-PCR were performed using an in-house RT-PCR on the automated
- 127 molecular diagnostic platform targeting the E gene <sup>13–15</sup> or using the SARS-CoV-2
- 128 test of the Cobas® 6800 instrument (Roche, Basel, Switzerland)<sup>16</sup>. The cycle
- 129 threshold (cycle when the RT-PCR was positive, i.e above the threshold of
- 130 fluorescence) was provided automatically by the instruments by using the default
- 131 parameters. Viral load was then obtained by converting (CT) of the RT-PCR
- 132 instruments, using the formula logVL=- 0.27Ct+13.04, as previously reported <sup>17,18</sup>.

#### 133 Outcomes

134 The primary outcome was the proportion of SARS-CoV-2 positive children detected

135 from saliva samples and NP swabs by RT-PCR assays. The secondary outcome was

- 136 the viral loads of SARS-CoV-2 measured by RT- PCR assays on saliva and NP
- 137 samples

#### 138 Statistical analysis

139 The estimated sample size was 50 positives among 500 cases tested to have a

- 140 precision of +/-2% on the detection rate if the latter was 20%. All patients having a
- result available for the 2 tests were included in the study analysis population.
- 142 Standard descriptive and comparative statistics were performed. The Chi-square test

143	was used to compare categorical variables between groups, as appropriate for
144	comparison between proportions. A Student t-test was used to compare continuous
145	variables when the normality of the distribution was visually accepted. For skewed
146	data, we derived medians and used the Mann–Whitney method for comparison. We
147	estimated the detection rate and sensitivity of each test with 95% CIs. The sensitivity
148	of saliva and NP samples was first calculated by using each other as the gold
149	standard. Next, a composite gold standard combining any positive RT-PCR result
150	reported from saliva and/or NP swabs was used to determine the sensitivity of both
151	samples. Stratified subgroup analyses for different age groups were conducted.
152	Participants were divided into 3 age groups: 0-6, ≥6-12, and ≥12 years of age and 3
153	symptom duration groups: 0-3, $\geq$ 4-7, and >7 days . Post-hoc analyses using the
154	Bonferroni correction were performed between age groups (age group effect: p
155	< 0.017 (0.05/3)) that presented statistically significant different detection rates and
156	sensitivities. Univariable linear regression was used to compare the clinical correlates
157	(duration of symptoms and age of patients) to NP or saliva sample viral loads.
158	Statistical analyses were computed using R software, v 3.6.1, and the 2019 R Studio
159	interface (R Studio Team, Boston, MA).

160 Results

# 161 Patient characteristics

Eight hundred and seventy-eight children and adolescents were screened between
November 4<sup>th</sup> and December 12<sup>th</sup>, 2020 for SARS-CoV-2. Among them, 405 children
were included in this study, of whom the 397 who had both NP and saliva samples
collected were included in the analyses. The mean age was 12.7 years (Standard
Deviation (SD) 3.8, range 1.2 to 17.9). One hundred and ninety-two patients (48.3%)

were females. The characteristics of the patient population stratified by SARS-CoV-2
 positive and negative results are summarized in Table 1.

169	The mean time between the onset of symptoms and the collection of the NP and
170	saliva samples was 2.4 days (SD 1.8, range 0 to 10) with no significant differences
171	reported in the duration of symptoms between children under 12 years of age and
172	those aged 12 and over (p=0.697). A vast majority of children of $\geq$ 12 years of age
173	presented at least one major symptom (89.9%), mostly sore throat (68.6%), cough
174	(49.5%), fever (25.6%), dysgeusia (13.4%) and anosmia (10.5%). The remaining
175	10.1% (28/278) suffered from at least one minor symptom while having close contact
176	with a documented COVID-19 case. From children <12 years of age, 81.5 % (97/117)
177	presented with fever (47.9%) and/or a severe cough (52.1%) associated at least with
178	a bad general condition, other manifestations suggestive of COVID-19 or symptoms
179	lasting more than 3 days. The remaining 18.5% (22/117) suffered from at least one
180	symptom suggestive of COVID-19 and had close contact with a documented COVID-
181	19 case.

182

#### 183 Detection rates of NP RT-PCR and saliva RT- PCR

Of the 397 participants included in the analyses, 91 (22.9%; 18.8-27.1%) tested positive by saliva samples, 101 (25.4%; 21.2-29.7%) by NP swabs, and 106 (26.7%; 22.4-31.1%) by any of the 2 samples. Detection rates were equivalent for both NP and saliva specimens (-8.7 to 3.7%, p=0.457). Respectively 15 and 5 children were detected positive only on NP swabs or saliva specimens. The detection rates by age categories (0-6,  $\geq$ 6-12, and  $\geq$ 12 years of age) were significantly different for saliva samples (p=0.007) but not for NP swabs (p=0.070). Yet, this remained only

191statistically different in post-hoc analyses between the age groups of 0-6 years and192 $\geq$ 6-12 years with a higher detection rate among children of  $\geq$ 6-12 years of age (3.2%)

193 vs 30.7 %, p=0.004) (Figure 1)

194 Diagnostic test performance (sensitivity, specificity) of NP RT-PCR and saliva RT-

195 *PCR* 

196 Using NP as the gold standard, the sensitivity of saliva was 85.2% (95%CI 78.2-

197 92.1%); in contrast, when saliva was considered the gold standard, the sensitivity of

198 NP was 94.5% (95%CI 89.8-99.2%) (p=0.058). The sensitivity of saliva RT-PCR was

dependent on NP VLs and was maximal with a viral load of 10<sup>6</sup> cp/ml. (Table 2 and

Figure 2). When using the composite reference as the gold standard, the respective

sensitivity of saliva and NP swabs was 85.9% (95%Cl 79.2-92.5%) and 95.3%

202 (95%Cl 91.3-99.3%) (p=0.034). When stratified by age groups, the respective

sensitivity of saliva and NP swabs was 89.9% and 97.1% in children aged ≥12 years

and 84.4% and 90.6% in children ≥ 6 to 12 years of age. In children under 6 years of

age, 4 patients were detected positive from NP swabs, whereas only one child was

206 documented positive from saliva. As a result, the reported sensitivity was only 25%

207 for saliva PCR and 100% for NP swabs in this subgroup. The reported sensitivity was

significantly different between age groups for saliva samples (p=0.0001) but not for

209 NP swabs (p=0.320). Yet, in post-hoc analyses, sensitivity for saliva remained

210 statistically different only between the 0-6 year subgroup compared to the one

including children of 12 years of age and onwards (25% vs 89,9%, p=0.003). When

212 stratified by the duration of symptoms, the respective sensitivity of saliva and NP

swabs was 89.5% and 95.3% in patient with symptom duration < 4 days (95%Cl -

14.8 to 3.2%, p=0.249) and 70.0% and 95.0% in those with symptom duration

- 215 (95%Cl -52.2 to 2.2%, p=0.096)  $\geq$  4 to 7 days. Only 3 patients had symptoms above
- 216 7 days and all were tested negative from both samples.

217 Viral loads

- 218 Figures 3A and 3B display the distribution of VLs and CT by analyzed specimen. VLs
- 219 documented from saliva were significantly lower compared to those reported from
- paired NP swabs (median 8.7 cp/ml  $x10^4$ ; IQR 1.2 $x10^4$ -5.2 $x10^5$ ; vs median

4.0x10<sup>7</sup> cp/ml; IQR 8.6x10<sup>5</sup>-1.x10<sup>8</sup>; p<0.001, 95Cl: -4.5x10<sup>2</sup> to - 7.7x101). VLs

- 222 measured from saliva increased significantly with age but not with the duration of
- symptoms (Figure 4A/B). VLs measured from NP were not affected by age. (Figure
- 224 4A).

#### 225 Comparison of discordant NP and saliva RT-PCR results

226 Table 3 displays the characteristics of the 15 children with NP swabs only positive 227 compared to the 86 documented positive from both NP swabs and saliva samples. 228 Children with isolated SARS-CoV-2 positive NP swabs were significantly younger (p=0.034) and with significantly lower NP VLs (median  $5.6 \times 10^3$  vs  $3.9 \times 10^7$ , p<0.001) 229 230 compared to those with both saliva and NP positive specimens. In addition, they 231 were not able to drool at the end of saliva collection (p=0.002). Variables such as the 232 duration of symptoms or the person who performed the procedure did not affect the 233 above findings. The 5 patients who had isolated positive saliva samples were all 234 males, had a median age of 11.1 y (10.3-14.6), and presented with median VLs of  $4.0x10^{3}$  cp/ml ( $1.1x10^{3}$ - $8.8x10^{3}$ ). 235

# 237 Discussion

238	The overall detection rate for SARS-CoV-2 between saliva and NP specimens by RT-
239	PCR was comparable. However, a significantly lower sensitivity was reported from
240	saliva specimens compared to NP swabs when compared to any positive test. Yet,
241	the sensitivity of saliva increased with VLs and was equivalent to NP swabs when
242	using a VL threshold of $\ge 10^4$ copies/ml. The procedure of saliva collection and
243	younger age affected the detection of SARS-CoV-2 in saliva. In contrast, the duration
244	of symptoms over 7 days of onset did not significantly affect the sensitivity of SARS-
245	CoV-2 detection in saliva.
246	With more than twice as many children included $^{8}$ , this study is by far, the largest
247	cohort reporting on the performance of saliva specimens in children. As supported by
248	another study including children $^8$ and other studies conducted in adults $^{10,19}$ , a
249	detection rates slightly lower of SARS-COV-2 were reported from saliva as compared
250	to NP specimens, yet still supporting the use of saliva as an alternative to NP swabs
251	in children. Moreover, our findings are in line with the RADICO study conducted in
252	symptomatic adults, that used the same saliva collection approach <sup>10</sup> . In contrast,
253	other studies indicated a poor concordance between NP and saliva specimens <sup>9,20,21</sup> ,
254	likely as a result of using different sampling procedures that did not necessarily
255	include saliva drooling. In addition, the inclusion of adults and children with a variable
256	duration of symptoms upon testing and asymptomatic patients possibly limited their
257	conclusions.

The sensitivity of RT-PCR assays reported from saliva was lower compared to NP swabs and the gold standard test, albeit only reaching statistical difference when compared to any positive test. This difference in sensitivity is likely explained by a 2

261	log lower VL detection in saliva compared to NP samples as evidenced elsewhere
262	<sup>9,10,22</sup> . Furthermore, SARS-CoV-2 detection in saliva is dependent on viral loads and
263	reaches an equivalent sensitivity to NP swabs for NP VL thresholds of 10 <sup>4</sup> copies/ml.
264	Recent studies <sup>23–25</sup> suggest that no cultivable viable virus is detected from patients
265	with VLs under the threshold of $10^4$ copies/ml. Altogether ours and others findings
266	suggest <sup>8</sup> that children detected SARS-CoV-2 negative from saliva samples
267	presented VLs under the threshold of 10 <sup>4</sup> copies/ml from their NP and were thereby
268	potentially less contagious. The use of saliva as an alternative to NP for SARS-CoV-
269	2 detection in children would thus limit quarantine measures to most contagious
270	children <sup>26</sup> .

271 Younger age significantly affected the detection rates and the sensitivity of SARS-272 CoV-2 in saliva as supported by a significantly reduced sensitivity of saliva 273 documented among children under 6 years of age compared to those of 12 years of 274 age and onwards. Furthermore, children who only detected positive from their NP 275 swabs were significantly younger compared to those documented SARS-CoV-2 276 positive from both specimens. The significant linear association documented 277 between age and VLs supported that lower VLs documented among younger 278 children likely affected the sensitivity of saliva for SARS-CoV-2 detection. Yet, 279 children under 6 years of age only represented 8% of our cohort, thereby limiting our 280 conclusions. In addition, the incomplete procedure for saliva collection observed 281 among younger children might have impacted the sensitivity, as most of the 15 282 children only documented SARS-CoV-2 positive from their NP swabs were not able 283 to drool. Yet, data from the RADICO study reported no impact of drooling on the sensitivity of saliva nor the VL count <sup>10</sup>. Whether drooling affects the sensitivity of 284 285 saliva remains an open debate and should be investigated in future pediatric studies.

286 Furthermore, drooling into the tube also raises biosafety concerns. The edge of the 287 tube can be contaminated thereby questionning the use of precautionary measures. 288 Duration of symptoms over 7 days of onset did not significantly affect the sensitivity of SARS-CoV-2 detection in saliva as already supported in other adult <sup>19</sup> and 289 paediatrics <sup>9</sup> studies. 290 291 Strengths of the current study include the largest pediatric sample size collected so 292 far in addition to the detailed prospectively collected information. Limitations are 293 predominantly related to the inclusion of outpatients and not hospitalized nor 294 asymptomatic children, which might affect the generalizability of our findings. 295 Furthermore, young children were under-represented and only a few of them were 296 detected SARS-CoV2 positive, thus limiting extrapolation to this age-group. In 297 addition, our study was conducted during a high prevalence of SARS-CoV-2 (up to 298 30%), thereby affecting our positive predicted values. Finally, our study was 299 conducted before the introduction of 501Y mutants in Switzerland, which currently 300 represent 8 to 15% of the analyzed samples. As such, we were not able to compare 301 the performance of mutant typing in saliva vs NP. Yet, recent evidence supports that the lower VLs detected from saliva limit mutant typing analyses <sup>27</sup>. 302

## 303 **Conclusion:**

In conclusion, saliva is a reliable alternative for SARS-CoV-2 detection among
symptomatic children. Saliva collection being a non-invasive easy procedure will
facilitate large-scale screening in children and thus provide more evidence on the
impact of SARS-CoV-2 in children.

### 309 Funding

310 The saliva PCR were paid for by the cantonal health authorities.

#### 311 Acknowledgments:

- 312 We thank Marion de Vallière and Maria Daniela Garrido for help in patient
- 313 recruitment, the patients for participation in this study, and the health authorities of
- the Canton de Vaud for their support. We would like to thank the Vidy-Med team and
- 315 the Montétan screening site teams for the recruitment of participants. We thank all
- 316 the team of the Laboratory of Molecular Diagnostics of the Institute of Microbiology
- 317 and Anne Tabard-Fougère for her help in the statistical analyses and figure
- 318 elaboration.

#### 319 Conflict of interest

320 None

# 321

## 322 <u>Bibliography:</u>

- 3231.Marcel S, Christian AL, Richard N, et al. COVID-19 epidemic in Switzerland: On the324importance of testing, contact tracing and isolation. Swiss Med Wkly. 2020;150(11-32512):4-6. doi:10.4414/smw.2020.20225
- Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities
   in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med*. 2020;58(7):1070-1076. doi:10.1515/cclm-2020-0285
- Hanson KE, Caliendo AM, Arias CA, et al. *The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing Authors.*;
   2020:1-70. www.idsociety.org/COVID19guidelines/dx.
- 3324.Li L, Shim T, Zapanta PE. Optimization of COVID-19 testing accuracy with nasal333anatomy education. Am J Otolaryngol Neck Med Surg. 2020;42(1):1-4.
- Kim YG, Yun SG, Kim MY, et al. Comparison between saliva and nasopharyngeal swab
  specimens for detection of respiratory viruses by multiplex reverse transcription-PCR. *J Clin Microbiol.* 2017;55(1):226-233. doi:10.1128/JCM.01704-16

337 338 339	6.	Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2. <i>JAMA Intern</i> <i>Med.</i> 2021:1-8. doi:10.1001/jamainternmed.2020.8876
340 341 342	7.	Ruggiero A, Sanguinetti M, Gatto A, Attinà G, Chiaretti A. Diagnosis of COVID-19 infection in children: Less nasopharyngeal swabs, more saliva. <i>Acta Paediatr Int J Paediatr</i> . 2020;109(9):1913-1914. doi:10.1111/apa.15397
343 344 345	8.	Yee R, Truong T, Pannaraj PS, et al. Saliva is a promising alternative specimen for the detection of SARS-CoV-2 in children and adults. <i>J Clin Microbiol</i> . 2020;(November). doi:10.1128/JCM.02686-20
346 347	9.	Cousins JN, Teo TB, Tan ZY, Wong KF, Chee MWL, Chee MWL. Saliva is not a useful diagnostic specimen in children with Coronavirus Disease 2019. 2020.
348 349 350	10.	Jean-Marc S, Miauton A, Petrovic D, et al. Antigen rapid tests , nasopharyngeal PCR and saliva PCR to detect SARS-CoV-22: a prospective comparative clinical trial. <i>medRxiv</i> . 2020. doi:doi.org/10.1101/2020.11.23.20237057
351 352 353 354 355 356 357	11.	BAG, SSP, Association professionelle de la pédiatrie Ambulatoire. Recommandation sur la procédure à suivre pour les enfants symptomatiques de moins de 12 ans et les autres personnes fréquentant les écoles et les structures d'accueil parascolaires et extrafamiliales et indications de test chez les enfants de moins de 12. https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-ausbrueche- pandemien/2019-nCoV/testkriterien- kinder.pdf.download.pdf/Criteres_de_test_pour_les_enfants.pdf. Published 2020.
358 359 360	12.	GIC Delaware. Delaware COVID-19 Saliva Test Instructions. https://www.youtube.com/watch?v=Eb3vSTc150U&feature=emb_logo. Published 2020.
361 362	13.	Corman VM, Landt O, Kaiser M, et al. Detection of 2019 -nCoV by RT-PCR. <i>Euro</i> Surveill. 2020;25(3):1-8.
363 364 365	14.	Pillonel T, Scherz V, Jaton K, Greub G, Bertelli C. Letter to the editor: SARS-CoV-2 detection by real-time RT-PCR. <i>Eurosurveillance</i> . 2020;25(21):1-2. doi:10.2807/1560- 7917.ES.2020.25.21.2000880
366 367	15.	Greub G, Sahli R, Brouillet R, Jaton K. Ten years of R&D and full automation in molecular diagnosis. <i>Future Microbiol</i> . 2016;11(3):403-425. doi:10.2217/fmb.15.152
368 369 370	16.	Roche Molecular Diagnostics. Cobas® 6800/8800 Systems: Specifications. https://diagnostics.roche.com/content/dam/diagnostics/Blueprint/en/pdf/rmd/RMD _cobas_6800_8000 _07353898001_4_Systems_SpecTech_SS-1.pdf. Published 2015.
371 372 373	17.	Jacot D, Greub G, Jaton K, Opota O. Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. <i>Microbes Infect</i> . 2020;22(10):617–621. doi:10.1016/j.micinf.2020.08.004
374 375 376 377	18.	Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a high- throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples. Onya. <i>Pathog Dis</i> . 2020. doi:10.1093/femspd/ftaa061
378 379	19.	Simonov M, Datta R, Handoko R, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. <i>N Engl J Med</i> . 2020;383:1283.

380 381	20.	Silva RCM da, Marinho LCN, Silva DN de A, et al. Saliva as a possible tool for the SARS- CoV-2 detection: A review. <i>Travel Med Infect Dis</i> . 2020;38:1-12.		
382 383 384	21.	Czumbel LM, Kiss S, Farkas N, et al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. <i>Front Med</i> . 2020;7(August):1-10. doi:10.3389/fmed.2020.00465		
385 386 387	22.	Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Clin</i> <i>Infect Dis</i> . 2020;27(Xx Xxxx):9-11. doi:10.1093/cid/ciaa848		
388 389 390	23.	L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. <i>Emerg Infect Dis</i> . 2020;26(10):2494-2497. doi:10.3201/eid2610.202403		
391 392 393 394	24.	Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. <i>Eurosurveillance</i> . 2020;25(32):1-5. doi:10.2807/1560- 7917.ES.2020.25.32.2001483		
395 396 397	25.	Jaafar R, Aherfi S, Wurtz N, et al. Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates. <i>Clin Chem Lab Med</i> . 2020:1-8. doi:10.1093/cid/ciaa1491		
398 399 400 401	26.	Turner F, Vandenberg A, Slepnev VI, Car S, Starritt RE, Seger M V. Post-Disease Divergence in SARS-CoV-2 RNA Detection between Nasopharyngeal, Anterior Nares and Saliva/Oral Fluid Specimens - Significant Implications for Policy & Public Health. <i>medRxiv Prepr</i> . 2021:1-19.		
402 403 404 405	27.	Leung K, Shum MH, Leung GM, Lam TT, Wu JT, Ty T. Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. <i>Eurosurveillance</i> . 2020;26(1):2020.12.20.20248581. doi:10.2807/1560-7917.ES.2020.26.1.2002106		
406				
407	Figu	re captions		
408	Figu	re 1: Detection rate for NP and saliva PCR by age categories		
409	NP=	Nasopharyngeal		
410	Figu	re 2: Sensitivity of saliva PCR in relation to NP viral loads		
411	NP=]	Nasopharyngeal		
412	Figure 3: Distribution of viral load and CT according to the type of sample			
413	NP=]	Nasopharyngeal		
414	Figure 4: Relation of viral loads to symptom duration and age			

# A) Distribution of Positive PCR Saliva by age

**B)** Distribution of Positive PCR NP by age









# Table 1. Characteristics stratified by SARS-CoV-2 positive or negative results

#### Legend: NP: Nasopharyngeal swab, SD= Standard Deviation

Characteristics	All, n=397	SARS-CoV-2 positive, n=106	SARS-CoV-2 negative, n=291	P value	95% Confidence Interval
Demographics					
Female, II (%)	192 (48 3%)	47 (44 3%)	145 (49.8%)	0 393	-17 2 to 6 2%
Age, mean years (SD)	12.7 (3.8)	12.7 (3.7)	12.6 (3.8)	0.904	-0.8 to 0.9
<12 years, n (%)	119 (30%)	36 (34.0%)	83 (28.5%)	0.356	-5.6 to 16.5%
Duration of symptoms, mean days (SD)	2.4 (1.8)	2.3 (1.6)	2.5 (1.8)	0.428	-0.5 to 0.2
Saliva sampling:					
Able to drool saliva, n (%)	368 (92.7%)	100 (94.3%)	268 (92.1%)	0.588	-3.8 to 83%
Tested by the:					
Patient, n (%)	202 (50.9%)	59 (55.7%)	143 (49.1%)	0.300	-5.2 to 18.2%
Adult (Parent or caregiver), n (%)	187 (47.1%)	46(43.4%)	141 (48.5%)	0.436	-16.7 to 6.6%
Patient + adult n (%)	8 (4.5%)	1 (0.9%)	7 (2.4%)	0.608	-4.7 to 1.7%

**Table 2.** Sensitivity of saliva RT-PCR compared to NP RT-PCR stratified by viral loadthresholds.Legend: NP: Nasopharyngeal swab, VL= viral load

		Sensitivity			
VL≥	VL <1e+3	VL ≥1e+3	VL ≥1e+4	VL ≥1e+5	VL ≥1e+6
Saliva PCR Sensitivity	85.1%	88.7%	95.2%	97.3%	98.4%

**Table 3.** Characteristics stratified by the concordance of positive NP and saliva RT-PCR findings Legend: NP: Nasopharyngeal swabs, VL= viral loads, IQR= interquartile range

Characteristics	Negative saliva PCR NP PCR + n=15	, NP and saliva PCR +, n=86	P value	95% Confidence interval
Age, median (IQR)	11.2 (7.3-14.0)	14.1 (11.8-15.4)	0.034	-4.7 to -0.2
Female, n (%)	9 (60.0%)	45 (52.3%)	0.788	-23.2 to 38.5%
Duration of symptoms, median,	3 (1.5-4.5)	2 (1-3)	0.094	0 to 2
(IQR)				
NP viral load, median (IQR)	$5.6 \times 10^3$	$3.9 \times 10^7$	<0.001	$-1.5 \times 10^4$ to $-4.6 \times 10^2$
	$(1.5 \times 10^3 - 1.0 \times 10^4)$	$(8.6 \times 10^5 - 1.0 \times 10^8)$		
Tested by the:				
Participant, n (%)	7 (46.7)	50(58.1%)	0.586	-42.7 to 19.8%
Adult (Parent or caregiver), n (%)	8 (53.3)	35 (40.7 %)	0.529	-18.6 to 43.8%
Patient + Adult, n (%)	0 (0.0 %)	1(1.1%)	1.000	-4.6 to 2.3%
Able to drool saliva, n (%)	11(73.3%)	84(97.7%)	0.002	-50.9 to 2.2%

IQR= interquartile range